CLINICAL TRIAL SERVICES AGREEMENT This Agreement is made and entered into this 16th day of March 2007 by and between: HARVARD CLINICAL RESEARCH INSTITUTE, INC. ("HCRI") 930 Commonwealth Avenue Boston, Massachusetts 02215Clinical Trial Services Agreement • April 5th, 2007 • Vicor Technologies, Inc. • Surgical & medical instruments & apparatus • Massachusetts
CLINICAL TRIAL SERVICES AGREEMENT*Clinical Trial Services Agreement • October 24th, 2011 • Radius Health, Inc. • Blank checks • New York
This Clinical Trial Services Agreement (this “Agreement”) is entered into as of March 29, 2011 (“Effective Date”) by and between RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.
CLINICAL TRIAL SERVICES AGREEMENT This Agreement is effective October 4, 2011 (“Effective Date”) by and between: Harvard Clinical Research Institute, Inc. (“HCRI”)Clinical Trial Services Agreement • October 11th, 2011 • InspireMD, Inc. • Surgical & medical instruments & apparatus • Massachusetts
WHEREAS, InspireMD (“Sponsor”) desires to engage HCRI for the purpose of providing Clinical Trial Services, as defined in Exhibit A to this Agreement, which will serve as the Scope of Work and budget for the Agreement, for the protocol for the “MGuard Stent System Clinical Trial in Patients with Acute Myocardial Infarction” Study, which shall be developed by HCRI under a separate consulting agreement, with such Protocol being incorporated by reference; and
CLINICAL TRIAL SERVICES AGREEMENTClinical Trial Services Agreement • June 14th, 2012 • Advaxis, Inc. • Pharmaceutical preparations • Pennsylvania
This Clinical Trial Services Agreement (“Agreement”) is between Advaxis, Inc. (“Sponsor”), a for-profit corporation organized under the laws of Delaware, USA and holder of IND Number 13712, and the Gynecologic Oncology Group (“GOG”), a not-for-profit corporation organized under the laws of the District of Columbia, to conduct the Clinical Trial according to the Protocol attached as Exhibit A and incorporated by reference in this Agreement. The Principal Investigator for the GOG shall be Philip J. DiSaia, M.D. The Clinical Trial will be directed by Warner K. Huh, M.D. (“Study Chair”), according to the Protocol.
CLINICAL TRIAL SERVICES AGREEMENT*Clinical Trial Services Agreement • May 23rd, 2011 • Radius Health, Inc. • Blank checks • New York
This Clinical Trial Services Agreement (this “Agreement”) is entered into as of March 29, 2011 (“Effective Date”) by and between RADIUS HEALTH, INC., a Delaware corporation (“Radius”) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (“NB”) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 3Clinical Trial Services Agreement • August 6th, 2015 • Radius Health, Inc. • Pharmaceutical preparations
The parties wish to enter into this Amendment No. 3 effective as of July 8, 2015 (“Amendment Date”). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in this Agreement.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 9 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • May 6th, 2015 • Radius Health, Inc. • Pharmaceutical preparations
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 9 to Work Statement NB-1 (“Amendment No. 9”) effective as of 12 March, 2015 (“Amendment Date”). Capitalized terms used in this Amendment No. 9 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 1 TO WORK STATEMENT NB-2Clinical Trial Services Agreement • November 14th, 2013 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-2 (“Amendment No. 1”) effective as of November 6, 2013 (“Amendment Date”). Capitalized terms used in this Amendment No. 1 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-2.
ContractClinical Trial Services Agreement • December 5th, 2023
GILEAD SCIENCES, INC. GILEAD SCIENCES, INC. CLINICAL TRIAL SERVICES AGREEMENT SMLOUVA O POSKYTOVÁNÍ SLUŽEB V KLINICKÉM HODNOCENÍ This Clinical Trial Services Agreement (“Agreement”) is made effective as of its publication in Contract Register(“Effective Date”) by and between Gilead Sciences, Inc., a Delaware corporation having a principal place of business at 333 Lakeside Drive, Foster City, California 94404 “Gilead”), and Nemocnice Na Homolce, Registration No: 00023884, having an address at Roentgenova 37/2, 150 30 Praha 5, Czech Republic (“Service Provider”).Account IQVIA RDS Czech Republic s.r.o., Registration No. 24768651, place of business located at Pernerova 691/42, 186 00 Praha 8 – Karlín, Czech Republic (the “CRO”) is serving as Gilead's contract research organization for the Trial. Gilead and Service Provider are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” Tato Smlouva o poskytování služeb v klinickém hodnocení („Smlouva“) je
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 2 TO WORK STATEMENT NB-1Clinical Trial Services Agreement • June 22nd, 2012 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 2 to Work Statement NB-1 (“Amendment No. 2”) effective as of June 18, 2012 (“Amendment Date”). Capitalized terms used in this Amendment No. 2 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.
CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 1 TO WORK STATEMENT NB-3Clinical Trial Services Agreement • March 10th, 2014 • Radius Health, Inc. • Blank checks
Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-3 (“Amendment No. 1”) effective as of February 28, 2014 (“Amendment Date”). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.
